Advertisement

Malignancies of Lower Gastroenterological Tract

  • Stefano Fanti
  • Mohsen Farsad
  • Luigi Mansi
  • Paolo Castellucci
Chapter

Abstract

18F-FDG PET/CT has a limited use in detecting primary colorectal cancer. False-negative results may be present in small tumors or in mucinous lesions [1–3], while false positives have been observed in patients with Inflammatory Bowel Diseases (IBD) or previous diagnostic polypectomy [1]. With 18F FDG-PET being more accurate than CT in detecting lymph node metastases, conversely CT is more sensitive for liver metastases. Because of the high incidence of disease recurrence (30–40%), an integrated PET/CT examination, also using contrast media, may be requested in selected patients with a high probability of distant secondarisms. Furthermore, because FDG’s uptake is expression of tumor aggressiveness, PET/CT pre-therapeutic utilization is also suggested as a prognostic tool; similarly, it is important to acquire a basal study, when it is supposed to utilize FDG to evaluate therapeutic response in follow-up [4]. Nevertheless, in the preoperative initial staging of disease, 18F-FDG PET/CT is considered potentially useful, although not yet sufficiently validated as first-line procedure [5].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Stefano Fanti
    • 1
  • Mohsen Farsad
    • 2
  • Luigi Mansi
    • 3
  • Paolo Castellucci
    • 4
  1. 1.Metropolitan Nuclear Medicine of BolognaUniversity of BolognaBolognaItaly
  2. 2.Nuclear Medicine DepartmentCentral Hospital BolzanoBolzanoItaly
  3. 3.Section Health and Development, Interuniversity Research Center for Sustainability (CIRPS)NaplesItaly
  4. 4.Metropolitan Nuclear MedicineAOU S.Orsola-Malpighi HospitalBolognaItaly

Personalised recommendations